TY - JOUR
T1 - The addition of avibactam renders piperacillin an effective treatment for Mycobacterium abscessus infection in an in vivo model
AU - Meir, Michal
AU - Bifani, Pablo
AU - Barkan, Daniel
N1 - Publisher Copyright:
© 2018 The Author(s).
PY - 2018/12/13
Y1 - 2018/12/13
N2 - Treating M. abscessus infection is challenging due to the potent β-lactamase Bla Mab (Beta-lactamase of M. abscessus ) . Avibactam is a non-β-lactam, β-lactamase inhibitor shown to inhibit Bla Mab . We tested whether avibactem can render piperacillin effective against M. Abscessus. In-vitro, avibactam enhanced the activity of piperacillin by 16-32 fold, with no significant effect on meropenem. In an in-vivo Galleria mellonella model, meropenem and piperacillin/avibactam significantly decreased infection burden compared to untreated controls. Neither piperacillin nor avibactam alone had a significant effect.
AB - Treating M. abscessus infection is challenging due to the potent β-lactamase Bla Mab (Beta-lactamase of M. abscessus ) . Avibactam is a non-β-lactam, β-lactamase inhibitor shown to inhibit Bla Mab . We tested whether avibactem can render piperacillin effective against M. Abscessus. In-vitro, avibactam enhanced the activity of piperacillin by 16-32 fold, with no significant effect on meropenem. In an in-vivo Galleria mellonella model, meropenem and piperacillin/avibactam significantly decreased infection burden compared to untreated controls. Neither piperacillin nor avibactam alone had a significant effect.
KW - Avibactam
KW - Combination treatment
KW - MIC
KW - Mycobacterium abscessus
KW - Piperacillin
UR - http://www.scopus.com/inward/record.url?scp=85058626606&partnerID=8YFLogxK
U2 - 10.1186/s13756-018-0448-4
DO - 10.1186/s13756-018-0448-4
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 30564307
AN - SCOPUS:85058626606
SN - 2047-2994
VL - 7
JO - Antimicrobial Resistance and Infection Control
JF - Antimicrobial Resistance and Infection Control
IS - 1
M1 - 151
ER -